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Abstract
Background: Metformin is a widely prescribed antihyperglycemic agent that has been also associated with
multiple therapeutic effects in various diseases, including several types of malignancies. There is growing evidence
regarding the contribution of the epigenetic mechanisms in reaching metformin’s therapeutic goals; however, the
effect of metformin on human cells in vivo is not comprehensively studied. The aim of our study was to examine
metformin-induced alterations of DNA methylation profiles in white blood cells of healthy volunteers, employing a
longitudinal study design.
Results: Twelve healthy metformin-naïve individuals where enrolled in the study. Genome-wide DNA methylation
pattern was estimated at baseline, 10 h and 7 days after the start of metformin administration. The whole-genome
DNA methylation analysis in total revealed 125 differentially methylated CpGs, of which 11 CpGs and their associated
genes with the most consistent changes in the DNA methylation profile were selected: POFUT2, CAMKK1, EML3,
KIAA1614, UPF1, MUC4, LOC727982, SIX3, ADAM8, SNORD12B, VPS8, and several differentially methylated regions as novel
potential epigenetic targets of metformin. The main functions of the majority of top-ranked differentially methylated
loci and their representative cell signaling pathways were linked to the well-known metformin therapy targets:
regulatory processes of energy homeostasis, inflammatory responses, tumorigenesis, and neurodegenerative diseases.
Conclusions: Here we demonstrate for the first time the immediate effect of short-term metformin administration at
therapeutic doses on epigenetic regulation in human white blood cells. These findings suggest the DNA methylation
process as one of the mechanisms involved in the action of metformin, thereby revealing novel targets and directions
of the molecular mechanisms underlying the various beneficial effects of metformin.
Trial registration: EU Clinical Trials Register, 2016-001092-74. Registered 23 March 2017, https://www.
clinicaltrialsregister.eu/ctr-search/trial/2016-001092-74/LV.
Keywords: Metformin, Epigenetics, DNA methylation, White blood cells, Longitudinal study
* Correspondence: klovins@biomed.lu.lv
†Ilze Elbere and Ivars Silamikelis contributed equally to this work.
1Latvian Biomedical Research and Study Centre, Ratsupites Str. 1 k-1, Riga
LV-1067, Latvia
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Elbere et al. Clinical Epigenetics          (2018) 10:156 
https://doi.org/10.1186/s13148-018-0593-x
Background
Metformin is the first-line drug for type 2 diabetes
(T2D) therapy, used since 1950s [1]. Although there are
a great number of various studies on the metformin
pharmacogenomics, pharmacokinetics, and lately its
interaction with the gut microbiome, the details of the
molecular mechanisms of metformin action have not
been fully understood.
So far, there are only a few studies within the context
of metformin action and changes in one of the most
commonly studied epigenetic modifications—DNA
methylation. One of the targeted studies has shown that
metformin treatment of pregnant rats with gestational
diabetes can reduce methylation level of peroxisome
proliferator-activated receptor γ coactivator-1A
(PPARGC1A), therefore preventing the abnormal glyco-
lipid metabolism in their offspring [2]. In addition, a
genome-wide study of metformin effects on lymphoblas-
toid cell lines has revealed potential biomarkers for met-
formin’s anticancer response [3]. In the context of
possible molecular mechanisms of how metformin in-
duce changes in the methylation profile, a recent study
has proved that, in cancer cells, metformin can exert its
effects via regulation of the H19/SAHH axis [4]. This
has been supported by data showing that metformin
promotes global methylation by decreasing S-adenosyl-
homocysteine (SAH) intracellular levels in various cell
types, including non-cancerous [5]. One of the latest
studies have specifically shown metformin’s effect on
lowering the methylation levels at the metformin trans-
porter genes, resulting in higher expression levels in liver
tissue [6]. Studies describing other epigenetic effects of
metformin have shown its impact on various histone
modifications via multiple mechanisms, mostly AMPK
dependent, and effect on expression levels of numerous
miRNAs through increase in DICER protein levels as
well [7].
Nevertheless, there is a significant lack of information
on how metformin affects global epigenetic regulation in
non-cancerous cells or in cells obtained from
metformin-treated humans. Therefore, our aim was to
investigate the short-term effect of metformin on DNA
methylation profiles in blood cells from healthy volun-
teers. Here we compared the changes in DNA methyla-
tion in the same subjects before and after the metformin
intake.
Results
Characteristics of the study participants
We used Illumina Infinium 450k array to evaluate the
effect of metformin on DNA methylation in 12 healthy
volunteers. The characteristics of the study group are
summarized in Table 1. Samples, for analysis of the
methylation levels, from each participant were obtained
at three time points, further marked as M0 (before start-
ing a metformin therapy), M10h (10 h after the first met-
formin intake, before the second tablet), and M7d (time
point after 7 days of metformin administration). M10h
sample was chosen to evaluate effect of one metformin’s
dose; to ensure accuracy of this measurement, all study
participants were strictly instructed to take the second
metformin tablet only after the M10h blood sampling.
Differentially methylated CpGs
During the data preprocessing stage, 64,512 (13.29%)
probes were filtered out, leaving 421,000 probes for
downstream analysis. To detect differentially methylated
CpG sites/probes (DMPs), we applied limma analysis be-
tween contrasts at all three time points, i.e., baseline,
after 10 h and 7 days of metformin administration. The
model included the methylation values at the contrasted
time points, together with the cell-type estimations as
covariates. Comparing methylation values at M10h and
M0 samples, 72 differentially methylated CpG sites with
a false discovery rate (FDR) of < 0.05 were identified
after correction for multiple testing using the
Benjamini-Hochberg method. In the same way, 52
DMPs were found applying contrast between methyla-
tion levels at M7d and M0 and only one (cg07026010—
NUDCD3) in case of M7d with M10h comparison (full
list of significant CpGs is available in Additional file 1).
Of these, 43 (59.72%), 24 (46.15%), and 1 (100%) CpG
sites were hypermethylated, and 29 (40.28%), 28
(53.85%), and 0 (0%) CpG sites were hypomethylated
when contrast analyses were applied for M10h vs M0,
M7d vs M0, and M7d vs M10h respectively (Fig. 1). The
median absolute difference in beta values, comparing all
contrasts, was 0.013 (interquartile range (IQR), 0.006–
0.029) for statistically significant differentially methylated
probes. The average estimated genomic inflation factor
(λ) for all three contrasts before correction was 1.64 ±
0.28, and after including covariates, it was reduced to
1.30 ± 0.15. Additional evaluation of λ with qq-plots
depicted the same improvement ensured by including
covariates (data not shown).
Table 1 Characteristics of the study group
Characteristic Value
Female/male, n (%) 7 (58.3%)/5 (41.7%)
Age, years, mean ± SD 31.4 ± 6.7
BMI, mean ± SD 25.3 ± 3.5
ALAT*, U/l, mean ± SD 25 ± 13
Creatinine*, μmol/l, mean ± SD 68 ± 8.9
Fasting plasma glucose*, mmol/l, mean ± SD 5.1 ± 0.3
BMI body mass index, SD standard deviation, ALAT alanine aminotransferase
*Samples for hematological, biochemical tests were collected before
metformin administration
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Among the identified DMP, a total of 11 CpGs with the
most consistent changes in the DNA methylation profile
were emphasized (Fig. 2) based on two additional criteria.
First, we included all overlapping DMP at both contrasts
M10h vs M0 and M7d vs M0 (n = 5; cg03515060,
cg18394557, cg16013966, cg05638165, cg18824330). Sec-
ond, we selected probes if their median beta values at time
points M10h and M7h overlapped IQRs of M7h and M10h,
respectively. Also, IQRs of both time points could not over-
lap with IQR of time point M0 (n = 6; cg12740863,
cg16843994, cg12162450, cg19176072, cg01644741,
cg02622542). Of these 11 CpGs, 8 (72.73%) CpG sites dis-
played hypermethylation, while 3 (27.27%) CpG sites
showed hypomethylation when comparing methyla-
tion levels after the metformin use (at time points
M10h and M7d) with methylation levels before the
use of metformin (Fig. 2).
All identified 11 CpG sites corresponded to 11 genes
according to the 450k annotation file published by Price
[8] (Table 2). One of these CpG sites was located in
high-density CpG island, 7 CpG sites—in
intermediate-density CpG islands with 1 bordering
Fig. 1 Differentially methylated positions in all analyzed contrasts. Volcano plot showing raw − log10 (p value) versus log-fold change of M values and
the Manhattan plot showing the position of probes with their corresponding unadjusted p values across the genome in a M10h vs M0, b M7d vs M0,
and c M7d vs M10h sample comparisons. The significant CpG sites (after FDR correction) are highlighted in red. M0—before starting a metformin
therapy; M10h—10 h after the first metformin intake, before the second tablet; M7d—time point after 7 days of metformin administration
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high-density CpG island, and 3—in non-islands accord-
ing to HIL CpG classes.
To analyze the possible influence of circadian
changes on the methylation profile, firstly, we
searched our DMP list for the most common genes
associated with regulation of circadian rhythm, such
as BMAL1, PER1, PER2, PER3, ARNTL, CRY1, and
CRY2. Secondly, we evaluated the main known func-
tional roles of genes associated with the 125 DMPs,
and, thirdly, we used the results from pathway enrich-
ment analysis to find any connections with the circa-
dian regulation. In result of these steps, we did not
find any significant associations between the DMPs
and circadian rhythm.
Fig. 2 Methylation levels of the top 11 most significant CpGs across the investigated three time points, i.e., M0 (before starting a metformin
therapy), M10h (10 h after the first metformin intake, before the second tablet), and M7d (time point after 7 days of metformin administration),
together with their associated genes. Box plots depict median, maximum, minimum, 25th percentile, and 75th percentile. Dots beyond the
bounds of the whiskers represent outliers. * and ** denote significance levels 0.05 and 0.01 respectively
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The correlation between methylation and RNA expres-
sion level of the corresponding gene was verified using
targeted data form RNA-seq. Out of 11 genes tested,
only the expression of UPF1 (p − 0.024), MUC4 (p −
0.029), and KIAA1614 (p − 0.048) showed significant
correlation with the methylation of corresponding CpG
sites (Table 2).
Differentially methylated regions (DMRs)
During the DMR analysis, we found 13 regions with sig-
nificant differences in methylation levels (summarized in
Table 3). Five of the identified regions overlapped with
some of the significant DMPs but not with the 11 sites
prioritized by us.
Enrichment analysis
To evaluate the potential biological significance of the
impact of differentially methylated CpG sites, we per-
formed a gene set pathway enrichment analysis by using
the Ingenuity Pathway Analysis (IPA). All genes associ-
ated with significant differentially methylated probes
(FDR < 0.05) from different contrasts were selected.
Table 2 Characterization of the top 11 most significant CpG sites






















Significant in both of the
following contrasts: M10h vs
M0 and M7d vs M0
cg03515060 21 0.538 0.479 0.003 0.018 POFUT2 1984 Body − 0.184
cg18394557 17 0.406 0.286 0.003 0.047 CAMKK1 − 8799 Body − 0.042
cg16013966 11 0.428 0.395 0.034 0.037 EML3 − 308 1stExon;5’UTR;TSS1500 − 0.23
cg05638165 1 0.358 0.351 0.035 0.034 KIAA1614 14,198 Body − 0.337
cg18824330 19 0.363 0.419 0.043 0.022 UPF1 − 9944 Body − 0.382
Significant in one of the
contrasts and medians for






0.034 0.127 MUC4 − 26,158 0.37





0.040 0.059 SIX3 7515 NA





0.137 0.043 SNORD12B 39 Body,TSS1500 0.036
cg02622542 3 0.269 0.348 0.151 0.047 VPS8 − 2419 0.166
Statistically significant FDR values are marked in italics
5′UTR 5′ untranslated region, TSS transcription starting site
aTSS1500: Region 200–1500 base pairs upstream of the transcription start site
Table 3 Differentially methylated regions
Contrast Gene FDR Number of probes Chr Start (bp)a End (bp)a Transcription factorsb
M10h vs M0 EPHB1 1.60E−11 3 3 134,515,421 134,516,302 –
CDCA7L 3.83E−07 5 7 21,985,276 21,985,628 Nr1h3
CLVS2 8.21E−07 10 6 123,317,123 123,317,875 Nrsf
BACE2, MIR3197 1.38E−06 3 21 42,539,960 42,540,409 CTCF
EXPH5 5.76E−06 6 11 108,464,101 108,464,498 Cmyc; Egr1; FOXA1; MYC; Max; SP1;
KCNE4 1.50E−05 3 2 223,916,686 223,916,861 USF1
TTC38 1.50E−05 4 22 46,685,471 46,685,728 NA
TTC39A 1.51E−05 5 1 51,810,626 51,811,022 –
NA 2.17E−05 3 4 153,897,215 153,897,453 NA
NA 2.33E−05 3 10 132,891,318 132,891,371 NA
M7d vs M0 SFRP2 1.18E−11 28 4 132,891,371 154,711,183 CTCF; Egr1
GPR19 4.59E−10 11 12 12,848,515 12,849,588 E2F4; ZBTB33;
TMEM216 3.46E−07 7 11 61,159,601 61,159,837 CTCF; Egr1; Gabp; Yy1
aPhysical position (basepair, hg37)
bData from Ensembl 91 regulation resources [98], hg38
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Thus, 72 genes were selected from the M10h vs M0 con-
trast and included in the first pathway analysis, and 52
genes from the M7d vs M0 contrast and included in the
second pathway analysis. We did not include the only sig-
nificant result from the M7d vs M10h contrast. The top
enriched canonical pathways are summarized in Table 4.
In addition to the canonical pathways, we identified
nine enriched networks in the M10h vs M0 contrast,
and four in the M7d vs M0 comparison. The top
enriched networks with IPA score > 20 were as follows
(score/focus molecules): M10h vs M0—hematological
system development and function, cellular movement,
cell-to-cell signaling and interaction (28/13); hereditary
disorder, neurological disease, organismal injury and ab-
normalities (23/11). M7d vs M0—cell-to-cell signaling
and interaction, cellular assembly and organization, cel-
lular function and maintenance (48/19); cell morph-
ology, cell-to-cell signaling and interaction, cellular
assembly and organization (41/17). Two of the most
relevant networks are visualized in Fig. 3.
Discussion
The aim of our study was to examine metformin-induced
alterations in epigenetic regulation processes by perform-
ing genome-wide DNA methylation analysis in human
white blood cells followed by estimation of RNA expres-
sion levels of identified genes. We conducted our study in
order to understand the pathways affected by metformin
at real life physiological conditions in humans. This is ex-
tremely important taking into account the pleiotropic ef-
fects of metformin, and such studies may pinpoint
important novel targets not only for treatment of T2D but
also for other diseases. Various studies have shown that
the evaluated effects in the methylation profile of periph-
eral blood DNA, that is the only option to access repeated
tissue sampling in humans, are highly representative to
the changes in other organs [9–11]. It is known that the
DNA methylation pattern is highly subject specific and is
influenced by many factors making it very difficult to
identify the metformin-specific effects in a
case-control-based type of study. We therefore selected a
longitudinal design for this study, using short response
time in order to exclude the influence of other factors. We
also involved healthy volunteers to avoid a background of
any commonly studied diseases so far related with the
beneficial effects of metformin. One of our goals was to
detect the fastest practically measurable effect of metfor-
min on DNA methylation. Taking into account the known
high variability of metformin pharmacokinetics, the time
point when to evaluate the immediate and at the same
time most profound effect was chosen to be the impact of
one dose, and sampling time was selected at 10 h, before
the recommended administration time of the second dose.
Furthermore, M10h vs M0 sample comparison revealed
the highest number or DMPs, representing the significant
effect of one metformin dose.
To our best knowledge, this is the first study showing
the metformin-mediated change of DNA methylation in
healthy individuals already 10 h after administration.
From the pool of 125 significantly modified sites, we pri-
oritized 11 differentially methylated CpG with the largest
and most consistent changes in beta values at different
contrasts.
We assumed that some methylation changes measured
at 10 h (M10h) could be caused by the circadian rhythm,
which has been well described before and proven to be a
driver of dynamic gene expression [12]. To avoid any
false conclusions about the epigenetic targets of metfor-
min, we paid specific attention to the presence of genes
involved in the circadian rhythm among regions cover-
ing DMPs. We also evaluated this possibility by focusing
on two contrasts that represent the different methylation
profiles of DNA purified from blood samples that were
collected in two distinct time points of the day—M7d vs
M0 and M7d vs M10h. We did not observe any overlap-
ping DMPs between the particular contrasts, suggesting
no significant influence of the circadian rhythm on the
DNA methylation in our data. Surprisingly, we observed
only one significant DMP comparing M7d and M10h
time points, providing a strong support for the fact that
Table 4 Top enriched canonical pathways by IPA
Contrast Pathway p value
M10h vs M0 Unfolded protein response 8.82 × 10−3
Salvage Pathways of Pyrimidine Deoxyribonucleotides 0.021
Glycogen Degradation II 0.031
Glycogen Degradation III 0.036
Granzyme B Signalling 0.041
Gα12/13 Signalling 0.046
Lipid Antigen Presentation by CD1 0.048
M7d vs M0 S-Methyl-5-thio-α-D-ribose 1-phosphate Degradation 6.82 × 10−3
Gustation Pathway 0.025
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observed methylation changes are indeed caused by met-
formin rather than other factors changing during the
trial, such as diet or circadian cycle.
Genes corresponding to the top-ranked DMPs represent
the main functional groups associated with previously de-
scribed targets of metformin therapy: regulatory processes
of energy homeostasis, inflammatory responses, tumori-
genesis, and neurodegeneration. The criteria based on the
comparison of median beta values and IQRs (see the “Re-
sults” section) were chosen to avoid bias in prioritization
and would allow to include potentially important DMPs
in addition to only those being significant at both M10h
vs M0 and M7d vs M0 contrasts.
Interestingly, we found DMP within CAMKK1 gene—
one of two highly homologous genes coding for Ca2
+/calmodulin-dependent protein kinase kinases
(CaMKK) [13]—with CaMKK2 being a known regulator
of AMP-activated protein kinase (AMPK). Despite the
fact that only CaMKK2 has been proven to form a stable
complex with AMPK, both isoforms of the CaMKK are
capable of phosphorylating the AMPKα subunit at
Thr-172 in vitro [14, 15]. From our data, the differen-
tially methylated CpG close to the CAMKK1 TSS to-
gether with negatively correlated mRNA expression data
as the result of metformin administration suggests a po-
tential contribution of CaMKK1 in the AMPK-mediated
mechanism of metformin anti-diabetic action.
Furthermore, it is known that metformin exerts its ef-
fects also via AMPK-independent mechanisms [16], as
shown by CaMKK1 ability to mediate glucose uptake in
muscle cells independently from AMPK and Akt [17], in
that way suggesting that methylation level changes in
CaMKK1 could be a part from an alternative pathway
responsible for the therapeutic effects of metformin.
Additionally, we identified a differentially methylated
CpG site near the transcription factor coding gene SIX3
[18]. Downregulation of SIX3 due to the methylation of
the SIX3 promoter is observed in lung adenocarcinoma
tissues and lung cancer cell lines, where mRNA expres-
sion of the gene is also associated with higher survival
rate [19]. Some research suggest SIX3 linkage to diabetes
from genetic studies [20] and show SIX3 as possible
regulator of insulin production in β-cells in an
age-dependent manner [21]. Lowered methylation level of
CpG near the SIX3 TSS shown in our data suggests the
DNA methylation as another potential epigenetic mech-
anism involved in SIX3 expression regulation. SIX3 is not
expressed in human white blood cells [22], explaining the
absence of reads corresponding to SIX3 in our RNA-seq
data, but gene expression may manifest in other tissues.
So far, normalized insulin production itself has not been
considered as a therapeutic effect of metformin, although
it might be affected along with metformin-induced im-
provements of insulin sensitivity [23].
Our data also show ADAM8 as a considerable poten-
tial contributor in the anti-inflammatory action of met-
formin, that is, one of the known beneficial effects of
this medication [24]. ADAM8 is a cell surface protease,
Fig. 3 Top enriched networks from IPA. Green nodes—hypermethylated; red nodes—hypomethylated. a Cell-to-cell signaling and interaction,
cellular assembly and organization, and cellular function and maintenance (central predicted associated biological functions—tumorigenesis
processes) had an IPA score of 48. b Cell morphology, cell-to-cell signaling and interaction, and cellular assembly and organization (central
predicted associated biological functions—metabolism processes) had an IPA score of 41
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mainly expressed in granulocytes and monocytic cells,
where it conducts the regulation of monocyte adhesion
and migration [25–27]. Its contribution in the inflamma-
tory responses regarding neurodegenerative disorders,
allergy, asthma, and acute lung inflammation has been
widely described before [28–31]. Our data justify the
anti-inflammatory properties of metformin independ-
ently of diabetes status [24] and suggest the potential
contribution of ADAM8 in the process. Due to its ex-
pression in human white blood cells, ADAM8 might be
considered a promising biomarker for the detection of
metformin-induced anti-inflammatory responses while
reflecting inflammatory processes in adipocytes; how-
ever, further experimental evidence is required.
Many of the genes linked to the top-ranked DMPs are
functionally associated with various malignancies. The
most significant DMP in our study appeared to be situ-
ated in the body of POFUT2. O-Fucosyltransferase 2
encoded by POFUT2 is proved to restrict
epithelial-mesenchymal transition and affect cell motility
in mouse embryos [32], and is considered as a useful
prognostic biomarker in patients with glioblastoma and
adenocarcinoma [33, 34]. To our knowledge, there are
no reports yet describing POFUT2’s association with the
beneficial effects of metformin. Our data also show sev-
eral more DMPs located within or near the TSS of
tumor-related genes, including SNORD12B—previously
associated with colorectal and breast cancer pathogen-
esis [35–37], MUC4—promising prognostic marker and
therapeutic target in the case of pancreatic cancer [38–
40], KIAA1614 with promoter hypermethylation ob-
served in colon tissues from patients with ulcerative col-
litis as well as in colon cancer cell lines [41], and UPF1
with indisputably crucial role in the maintenance of gen-
ome stability, significantly implicated in various malig-
nancies [42–47].
The functions of two genes from the top DMPs’ asso-
ciated list are poorly defined. We identified increased
DNA methylation level close to the TSS of VPS8 gene.
VPS8 is an accessory subunit of CORVET complex, ne-
cessary for mediating multiple steps in the endocytic
pathway and required for fusion of early endosomes
[48]. Thus far, there is no conclusive data indicating the
possible effects of VPS8 dysregulation on phenotype in
humans [49–52]. Likewise, the function of long inter-
genic non-protein coding RNA 1249 (LINC01249/
LOC727982) is still not clear with only few reports on
genetic association of SNPs within the gene with infec-
tious disease and blood pressure [53, 54].
Overall, the DNA methylation has a repressive effect
on transcription factor binding; therefore, we used EN-
CODE data on transcription factor binding sites to iden-
tify such possible interactions [55, 56]. We detected
transcription factors CTCF, CTCFL, and Egr1 binding to
the genomic region overlapping the differentially methyl-
ated CpG within EML3 gene; out of these, CTCF is
proved to mediate glucagon production [57] and Egr1 is
responsible for insulin resistance [58]. Although there
are no data available to date, supporting direct metfor-
min impact on EML3 (nuclear microtubule-binding pro-
tein) [59] or describing EML3 contribution in
metformin therapeutic effects, increased expression of
EML3 in cultured human cells as a result of
metformin-1816 small molecule perturbation has been
reported before [60]. Likewise, the genomic region
within UPF1 gene, covering the top-ranked CpG site is
associated with CTCF, Egr1, and two more transcription
factors: MYC—involved in the pathogenesis of diabetes
[61], and PU1—initiating insulin resistance as well as
regulating lipolysis [62].
The detected DMRs, as well, could essentially be
grouped by connection to the processes currently known
to be affected by metformin. For example, the most sig-
nificant DMR was associated with EPHB1, which together
with other Ephrin receptors forms the largest subgroup of
the Eph receptor tyrosine kinase (RTK) family [63]. Un-
derexpression of the EphB1 protein is significantly associ-
ated with tumor progression in gastric carcinomas and
higher invasiveness of colorectal cancer cells, suggesting a
tumor-suppressive role of the protein and possible impli-
cation in the beneficial effects of metformin [64, 65].
Another noteworthy DMR was associated with
APP-cleaving enzyme 2 coding gene (BACE2) encoded
protein that cleaves amyloid precursor protein into
amyloid beta peptide, and is implicated in the pathogen-
esis of neurodegenerative diseases including Alzheimer’s
disease [66–68]. Interestingly, increased β-cell prolifera-
tion and glucose-stimulated insulin secretion resulting
from reduced Bace2 levels have been previously reported
[69]. In a mouse model of T2D, induced by the overex-
pression of human islet amyloid polypeptide, BACE2 de-
ficiency improved glucose tolerance, suggesting that
BACE2 inhibition might serve as a potential therapeutic
strategy for T2D treatment [70].
Another DMR is associated with SFRP2, Secreted Friz-
zled Related Protein 2. Methylation changes in the pro-
moter region of SFRP2 have been proposed as a potential
noninvasive biomarker for colorectal cancer [71, 72]. Its
mRNA is also expressed in mouse and human adipose tis-
sue, and elevated levels have positive correlation with BMI
and with abnormal glucose tolerance [73].
The pathway enrichment analysis revealed metformin’s
association with various pathways some of which already
has been described in connection with metformin action
but not in the context of epigenetic regulation. The top
enriched pathway after one dose of metformin—Unfolded
Protein Response (UPR)—has been shown to be one of the
main mechanisms of inducing apoptosis by metformin in
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acute lymphoblastic leukemia cells [74], and metformin-in-
duced UPR inhibition in kidney cells can explain metfor-
min’s beneficial effects [75].
One of the products of the top enriched pathway describ-
ing changes after week long metformin administration
(S-methyl-5-thio-α-D-ribose 1-phosphate Degradation) is
L-methionine, an essential amino acid in human organism.
Moreover, it is known that L-methionine is used for gener-
ation of S-adenosylmethionine (SAM) [76], which has been
depicted to be an essential part of metformin-induced in-
crease in global methylation levels as it accumulates in cells
during metformin therapy [5]. Taking into account the re-
sults from enriched pathways and the fact that we mostly
observe metformin-induced hypermethylation than hypo-
methylation, it is possible that activation of this particular
canonical pathway may contribute to the previously de-
scribed increase in SAM levels.
Although enriched networks (Fig. 3) are not directly
related to known metformin effects, the downstream
molecules of those associated with differential methyla-
tion levels in our study group are known to be involved
in various pathways related with T2D (e.g., AKT, ERK1/
2, JNK, P13K), insulin regulation processes [77], cancer
development mechanisms [78], and other.
The correlation between DNA methylation and gene
expression is complex and nonlinear [79]. The generally
accepted consequence of DNA methylation is transcrip-
tional repression; however, methylation in the tran-
scribed region might also demonstrate positive
correlation with mRNA expression [80]. In our study,
we did not detect a convincing correlation between
DNA methylation of top-ranked loci and transcription
level of corresponding genes; however, the influence of
methylation as well as gene expression itself are
tissue-specific and might be missed by focusing on single
type of cells only. Nevertheless, the significant correl-
ation observed between the expression levels of UPF1,
MUC4, KIAA1614, and the methylation level of the cor-
responding CpG sites provide evidence for a crucial con-
tribution of epigenetic regulation in the mechanism of
action of metformin, which results in specific alterations
of gene expression profiles.
Currently, it is not fully known whether metformin
has only an indirect effect on the epigenetic regulation
processes in the human organism via the previously de-
scribed H19/SAHH axis or through linking cellular me-
tabolism to the mechanisms needed for DNA
methylation [4, 5]. However, the methylation profile and
concentration of metformin used in cell type specific in
vitro experiments may significantly differ from the
physiological levels and observations in the affected cells
in human body. The large variation of SAH and SAM
levels in various cell types has been described [5]. In
addition, the previous studies evaluating the
metformin-induced methylation profile changes mostly
have been targeted; thus, it is not surprising that we did
not observe the DMPs at the same genes or pathways.
Major limitation of this study is the low sample size
even though there are number of reports using the same
number of individuals in their studies [81–84]. On the
other hand, we believe that this weakness is compen-
sated by the number of strengths in our design. First, we
used a longitudinal study design and it has been recog-
nized that, in similar time series studies, individuals can
be treated as their own controls before and during treat-
ment and sufficiently increase the power of the study
[85] compared to case-control design especially account-
ing for the inter-individual variability among study par-
ticipants. Secondly, the longitudinal design combined
with observation of methylation changes in the shortest
possible time allows us to minimize the effects of other
factors that can induce changes in methylation unrelated
to the metformin treatment. Thirdly, inclusion of
healthy subjects should have minimized false associa-
tions and conclusions arising from unaccounted treat-
ment status by metformin or other medications in T2D
patients, including the unknown true duration of T2D
before diagnosis. Finally, the use of genome-wide methy-
lation analysis allows us to observe unbiased effects and
find new metformin targets.
Another limitation in our study is the lack of clinical
and biochemical measures at all time points. In the same
time, it has been previously shown that metformin has
small or no effect of such measures as plasma glucose
level in healthy individuals [86, 87], and we decided not
to include those in study protocol.
Unfortunately, due to the lack of similar studies, we
were not able to support our findings from literature
and replication in other cohorts is needed.
Conclusions
This is the first study showing the immediate effect of
metformin on white blood cell DNA methylation in
humans at therapeutic doses. The gained knowledge
about the metformin-induced methylation profile
changes in healthy individuals can be used as basis for
further in vitro and in vivo studies, which are important
due to the growing number of various metformin thera-
peutic application possibilities in non-diabetic patients.
Methods
Study design
Study group involved 12 healthy metformin-naïve volun-
tary individuals. The involvement and sample collection
was organized in collaboration with the Genome Data-
base of Latvian Population (LGDB) [88]. Exclusion/in-
clusion criteria (Additional file 2) were defined
according to the requirements of concurrently ongoing
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clinical trial (registration number: 2016-001092-74
(www.clinicaltrialsregister.eu)), which also involves gut
microbiome analysis. Participants were included if they
matched the following criteria: have not used antibiotics,
immunosuppressive medicaments, corticosteroids, or
pharmaceutical-grade probiotics during the time period
of the past 2 months; have not been diagnosed with
oncological, autoimmune, chronical gastrointestinal tract
diseases, or T2D; have not had diarrhea in the past week;
and are not taking any other medications incompatible
with metformin. The research subjects received an
850-mg metformin tablet (Berlin-Chemie AG) twice a
day for a week. Samples for hematological, biochemical
tests were collected in certified clinical laboratory at fast-
ing state 1–3 days before starting the metformin admin-
istration. Whole blood samples for methylation analysis
were collected at three time points: (1) before starting
metformin therapy (morning, fasting state)—M0, (2) 10
h after first metformin intake, before the second tablet
(evening)—M10h, and (3) after 7 days of metformin ad-
ministration (morning, fasting state)—M7d. Throughout
the article, we have defined the measurement of 10-h
sample as the immediate effect of metformin.
Sample analysis
DNA isolation from whole blood samples using the
phenol-chloroform extraction method was performed by
Genome Database of Latvian Population (briefly de-
scribed before [89]). DNA samples were quantified with
Qubit® 2.0 Fluorometer using Qubit dsDNA HS Assay
Kit (TherfmoFisher Scientific, USA). For the bisulfite
conversion, the EZ DNA Methylation-Gold TM kit
(Zymo research, USA) was used according to the manu-
facturer’s instructions. DNA methylation was deter-
mined by the Illumina Infinium HumanMethylation450
BeadChip Array (Illumina, USA), using 500 ng of each
bisulfite-treated DNA sample.
Total RNA was isolated from whole blood samples
using PerfectPure RNA Blood Kit (5Prime GmbH, Ham-
burg, Germany). Ribosomal RNS depletion was done
with Low Input RiboMinus™ Eukaryote System v2
(Thermo Fisher Scientific, USA). For cDNA library prep-
aration, we used Ion Total RNA-Seq Kit v2 (Thermo
Fisher Scientific, USA), and sequencing was performed
on the Ion Proton™ System and Ion PI™ Chip (Thermo
Fisher Scientific, USA).
Data preprocessing and statistical analysis
IDAT files were imported using R package minfi [90].
Cell counts were estimated from methylation data using
Houseman algorithm [91] implemented in minfi.
Data preprocessing and normalization was done using
Enmix [92]. Briefly, probes with detection p value > 0.05
and probes with a multimodal distribution were filtered
out. Background correction was performed with the
function preprocessENmix using unused color channels
as a background parameter estimate. Probe intensities
were normalized using a quantile normalization method,
and probe type bias was adjusted using the Regression
on Correlated Probes (RCP) method [93]. Probes having
a SNP or single base extension annotation in CpG site
were excluded. Due to interrupted use of metformin by
one of the study subjects, the sample taken after 1 week
of metformin administration for that particular subject
was discarded.
Batch effect was removed from data using slide and subse-
quently subjects as covariates as they showed the strongest
influence on the probe methylation variability. Batch effect
was removed using ComBat [94] wrapped in the Enmix
package. Differentially methylated probes between time
points were identified using limma [95] on ComBat prepro-
cessed data, adjusting for the following cell types estimated
by minfi: CD8T, CD4T, NK, and Gran. Inflation factor of
p-value distribution was estimated using R package GenA-
BEL [96]. All analyses were performed using R (3.3.3).
Statistically significant DMRs were identified with
DMRcate software [97], FDR < 0.05. Threshold for mini-
mum number of probes within the region was set to
three. DMRs were estimated from methylation M values
using the individual CpG site significance threshold at
FDR < 0.05. The interval between individual significant
CpG sites had to be less than 1000 bp in the regions.
The bandwidth scaling factor was set as suggested in the
manual (C = 2). Regulatory information from Ensembl
91 regulation resources was added to identified DMPs
and DMRs using Ensembl Regulation API [98].
Pathway enrichment analysis was performed with the
IPA tool [99]. Information about enriched canonical
pathways and networks was obtained performing the
core analysis on all significant DMPs with FDR < 0.05.
RNA-seq data analysis
Reads were mapped against human reference genome
GRCh38, and read quantification was performed using
STAR (2.5.3a) [100]. Obtained per-gene read counts
were normalized using trimmed mean normalization
(TMM), and counts per million (CPM) values were cal-
culated with edgeR [101]. ComBat [94] implemented in
R package sva [102] was used to adjust CPM values for
subject-specific effects, and the Spearman correlation
was estimated for the adjusted CPM values and the beta
values for 11 selected CpG sites with SciPy [103].
Additional files
Additional file 1: Full results representing all CpGs within the analyzed
contrasts with significantly changed methylation levels, identified after
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correction for multiple testing using the Benjamini-Hochberg method.
(XLSX 21 kb)
Additional file 2: List of inclusion/exclusion criteria. (DOCX 14 kb)
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